# Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

> **NCT04915755** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Neoplasms, Breast

## Interventions

- **DRUG:** Niraparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04915755
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-28
- **Primary completion:** 2024-06-28
- **Final completion:** 2025-12-31
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04915755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04915755, "Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04915755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*